Healthy Clinical Trial
Official title:
Personalized Responses to Dietary Composition Trial 3
The PREDICT 3 study will build on previous research in over 2,000 individuals to further refine machine learning models that predict individual responses to foods, with the aim of advancing precision nutrition science and individualized dietary advice. The study incorporates both standardized and controlled dietary intervention, for the purpose of testing postprandial responses to specific mixed meals, in addition to a free-living period with a dietary record for measuring responses to a large variety of meals consumed in a realistic context, where the role of external factors (e.g. exercise, sleep, time of day) on postprandial responses may be determined. For the first time this PREDICT study is built on top of a commercial product which will allow access to a much larger group of participants who are already collecting large amounts of data through digital and biochemical devices that can contribute to science.
Status | Recruiting |
Enrollment | 250000 |
Est. completion date | December 20, 2024 |
Est. primary completion date | December 20, 2024 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Enrolled in the commercial ZOE testing program - Any sex - Minimum 18 years of age (minimum 19 years of age in Alabama and Nebraska due to state laws) - Body mass index (BMI) of greater than or equal to 16.5 kg/m2. - Living in the continental US states, other than in New York (excluded from the ZOE testing product also as they are unable to access the dried blood spot service provided by Quest), or living in the UK - Able and willing to comply with the study protocol and provide informed consent. - Under care for chronic medical conditions (including eating disorders, type 1 diabetes, type 2 diabetes), and confirm they have checked with their primary care physician that this study is safe for them (US cohort only) Exclusion Criteria: - Cannot safely eat the pre-made test meals which contain standard US ingredients, e.g. due to allergy or recent gastrointestinal surgery, or are unwilling to consume these foods. - Are pregnant. - Have had a heart attack (myocardial infarction), stroke/transient ischemic attack (TIA), or major surgery in the last two months. - Are unable to read and write in English, as the ZOE app is only available in English. |
Country | Name | City | State |
---|---|---|---|
United Kingdom | King's College London | London | |
United States | Zoe US Inc. | Needham | Massachusetts |
Lead Sponsor | Collaborator |
---|---|
Zoe Global Limited | Harvard School of Public Health (HSPH), Massachusetts General Hospital, Stanford University |
United States, United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Adherence (in sub-cohort) | Self-reported in-app question on daily frequency of adherence (categorical) | Time Frame: 12 months: Baseline, Weekly (0 to 4 weeks), monthly (5 to 52 weeks) | |
Other | Hunger (in sub-cohort) | Self-reported in-app question on hunger levels (categorical) | Time Frame: 12 months: Baseline, Daily (0 to 4 weeks), monthly (5 to 52 weeks) | |
Other | Weight (in sub-cohort) | Body Weight (kg) | Time Frame: 12 months: Baseline, Weekly (0 to 4 weeks), monthly (5 to 52 weeks) | |
Other | Bristol Stool Category (in sub-cohort) | Self-reported in-app Bristol Stool chart question (categorical) | Time Frame: 12 months: Baseline, Daily (0 to 4 weeks), monthly (5 to 52 weeks) | |
Other | Bowel Frequency (in sub-cohort) | Self-reported in-app question on bowel frequency | Time Frame: 12 months: Baseline, Daily (0 to 4 weeks), monthly (5 to 52 weeks) | |
Other | Energy (in sub-cohort) | Self-reported in-app question on energy levels (categorical) | Time Frame: 12 months: Baseline, Daily (0 to 4 weeks), monthly (5 to 52 weeks) | |
Other | Waist Circumference (in sub-cohort) | Self-reported in-app question on waist circumference | Time Frame: 12 months: Baseline, monthly (4 to 52 weeks) | |
Other | Hip Circumference (in sub-cohort) | Self-reported in-app question on hip circumference | Time Frame: 12 months: Baseline, monthly (4 to 52 weeks) | |
Primary | Glucose | Measurement of blood glucose by continuous glucose monitor (mmol/L) | 6-14 days | |
Primary | Gut microbiome species richness | Species count in fecal sample (as part of ZOE testing program) | 1 day | |
Primary | Blood Lipids | Measurement of baseline and 6-h post-prandial triglycerides (mmol/L) by dried blood sample (as part of ZOE testing program) | 1 day | |
Primary | Hunger and appetite assessment | Self-reported in-app question on energy levels (categorical) (as part of ZOE testing program) | 6-14 days | |
Primary | Glucose and HbA1c | Measurement of baseline glucose (mmol/L) and HbA1c (%) by dried blood sample (as part of ZOE testing program) | 2 days | |
Secondary | Dietary assessment | Weighed food log | 6-14 days | |
Secondary | Anthropometry | Weight (kg) (as part of ZOE testing program) | 1 day | |
Secondary | Anthropometry | Height (cm) (as part of ZOE testing program) | 1 day | |
Secondary | Dietary assessment | Diet history and portion size questionnaire about the preceding month (as part of ZOE testing program) | 1 month | |
Secondary | Bowel Type and Habit | Measurement by Bristol Stool Chart and Questionnaire (as part of ZOE testing program) | 6-14 days | |
Secondary | Perceived Energy Assessment | Self-reported in-app question on energy levels (categorical) (as part of ZOE testing program) | 6-14 days | |
Secondary | Covid-19 symptom assessment | Self-reported demographic and physical health symptoms, or lack thereof, reported on a daily basis (as part of ZOE testing program) | 6 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06052553 -
A Study of TopSpin360 Training Device
|
N/A | |
Completed |
NCT05511077 -
Biomarkers of Oat Product Intake: The BiOAT Marker Study
|
N/A | |
Recruiting |
NCT04632485 -
Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
|
||
Completed |
NCT05931237 -
Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults
|
N/A | |
Terminated |
NCT04556032 -
Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women
|
N/A | |
Completed |
NCT04527718 -
Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers
|
Phase 1 | |
Completed |
NCT04998695 -
Health Effects of Consuming Olive Pomace Oil
|
N/A | |
Completed |
NCT04107441 -
AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects
|
Phase 1 | |
Completed |
NCT04065295 -
A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225
|
Phase 1 | |
Completed |
NCT01442831 -
Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects
|
Phase 1 | |
Terminated |
NCT05934942 -
A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood
|
Phase 1 | |
Recruiting |
NCT05525845 -
Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI
|
N/A | |
Completed |
NCT05515328 -
A Study in Healthy Men to Test How BI 685509 is Processed in the Body
|
Phase 1 | |
Completed |
NCT04967157 -
Cognitive Effects of Citicoline on Attention in Healthy Men and Women
|
N/A | |
Completed |
NCT05030857 -
Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects
|
Phase 1 | |
Recruiting |
NCT04714294 -
Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers
|
Phase 1 | |
Recruiting |
NCT04494269 -
A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls
|
Phase 1 | |
Completed |
NCT04539756 -
Writing Activities and Emotions
|
N/A | |
Recruiting |
NCT04098510 -
Concentration of MitoQ in Human Skeletal Muscle
|
N/A | |
Completed |
NCT03308110 -
Bioavailability and Food Effect Study of Two Formulations of PF-06650833
|
Phase 1 |